Predicting and managing the progression of structural damage in rheumatoid arthritis: Where do we stand?

Clinical and Experimental Rheumatology

Volumn 30, Issue 4, 2012, Pages 459-463

  Govoni, M ^a   Caporali, R ^b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Disease progression; Rheumatoid arthritis; Treatment outcome

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CHLOROQUINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; EARLY DIAGNOSIS; EDITORIAL; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; PATIENT CARE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVITIS; SYSTEMATIC REVIEW (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PREDICTIVE VALUE OF TESTS; RHEUMATOLOGY; RISK FACTORS;

EID: 84867360804     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (37)

1. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
2. DE ROOY DP, VAN DER LINDEN MP, KNEVEL R, HUIZINGA TW, VAN DER HELM-VAN MIL AH: Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
3. LARD LR, VISSER H, SPEYER I et al.: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51.
4. VAN AKEN J, LARD LR, LE CESSIE S, HAZES JM, BREEDVELD FC, HUIZINGA TW: Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004; 63: 274-9.
5. SVENSSON B, HAFSTROM I: Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 2011; 29: S63-7.
6. MEASE PJ: The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol 2011; 29: 567-74.
7. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
8. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, KERSTENS PJ et al.: DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010; 69: 65-9.
9. VERSTAPPEN SM, JACOBS JW, VAN DER VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
10. SCHIPPER LG, VA HULST LT, GROL R, VAN RIEL PL, HULSCHER ME, FRANSEN J: Metaanalysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010; 49: 2154-64.
11. ALLAART CF, BREEDVELD FC, DIJKMANS BA: Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl 2007; 80: 25-33.
12. LUKAS C, VAN DER HEIJDE D, FATENAJAD S, LANDEWÉ R: Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis 2010; 69: 851-5.
13. KEYSTONE E: Recent concepts in the inhibition of radiographic progression with biologics. Curr Opin Rheumatol 2009; 21: 231-7.
14. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
15. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
16. LANDEWÉ R, VAN DER HEIJDE D, VAN DER LINDEN S, BOERS M: Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006; 65: 637-41.
17. ALETAHA D, SMOLEN J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S100-8.
18. BROWN AK, QUINN MA, KARIM Z et al.: Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
19. NAREDO E, COLLADO P, CRUZ A et al.: Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 2007; 57: 116-24.
20. TAYLOR PC, STEUER A, GRUBER J et al.: Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004; 50: 1107-16.
21. WAKEFIELD RJ, FREESTON JE, HENSOR EM, BRYER D, QUINN MA, EMERY P: Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. Arthritis Rheum 2007; 57: 1564-7.
22. SCIRÈ CA, MONTECUCCO C, CODULLO V, EPIS O, TODOERTI M, CAPORALI R: Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford) 2009; 48: 1092-7.
23. HAAVARDSHOLM EA, BOYESEN P, OSTERGAARD M, SCHILDVOLD A, KVIEN TK: Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008; 67: 794-800.
24. SMOLEN JS, HAN C, BALA M et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020-30.
25. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
26. LANDEWÉ R, VAN DER HEIJDE D, KLARESKOG L, VAN VOLLENHOVEN R, FATENEJAD S: Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006; 54: 3119-25.
27. KREMER JM, BLANCO R, BRZOSKO M et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
28. GENOVESE MC, PETERFY CG, EMERY P et al.: Evaluation of joint damage in RA patients treated with Rituximab: comparison of Genant- and Van Der Heijde-modified Sharp Radiographic Scoring. In: RHEUMATOLOGY ACO, ed. Annual Scientific meeting. Vol 57 (Abstr.) 2008: 5304.
29. KREMER JM, GENANT HK, MORELAND LW et al.: Results of a two-year followup study of patients with rheumatoid arthritis- who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58: 953-63.
30. WESTHOVENS R, ROBLES M, XIMENES AC et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68: 1870-7.
31. GENOVESE MC, MCKAY JD, NASONOV EL et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80.
32. COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
33. MARKATSELI TE, ALAMANOS Y, SAOUGOU I, VOULGARI PV, DROSOS AA: Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol 2012; 30: 31-8.
34. KURIYA B, ARKEMA EV, BYKERK VP, KEYSTONE EC: Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
35. EMERY P, GENOVESE MC, VAN VOLLENHOVEN R, SHARP JT, PATRA K, SASSO EH: Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009; 36: 1429-41.
36. VASTESAEGER N, XU S, ALETAHA D, ST CLAIR EW, SMOLEN JS: A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1114-21.
37. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.